 NEW YORK, Oct. 5, 2021 PRNewswire -- Mind Medicine MindMed Inc. NASDAQ: MNMD, NEO: MMED, DE: MMQ the Company, a leading biotech company developing psychedelic-inspired therapies, has agreed to partner with Sphe re Health a physician-founded employee benefits provider targeting treatments for people with severe mental illness to collect and analyze multimodal data in order to improve the understanding of a variety of biomarkers associated with mental illnesses including anxiety and affective disorders. MindMed and Sphere Health are jointly launching MM061302, a study using existing consumer technology to provide a robust data set, which may be used to develop more accurate machine learning tools in order to identify biomarkers that show association with and prediction of symptoms of anxiety and depression. 